On March 28, 2025, the Hengqin Guangdong-Macao In-Depth Cooperation Zone Executive Committee and the Shenzhen Stock Exchange successfully held a strategic coope
On December 18, 2024, Zhuhai Hengqin Yancheng Biotechnology Co., Ltd. was officially granted the patent for the “Preparation Method of Hypoxilin Analogues,” under patent number ZL202011353259.6.
On December 9, 2024, Academician Li Lanjuan of the Chinese Academy of Engineering, together with her delegation, visited Zhuhai Hengqin Yancheng Biotechnology C
From December 7 to 8, 2024, the 2024 World Life Science and Technology Conference and Academic Symposium on Engineering Science and Technology of the Chinese Ac
On February 15, 2024, we partnered with Tencent (Stock Code: 00700) to establish an AI-powered prediction platform for tumor neoantigen analysis. Leveraging art
On November 29, 2023, Hengqin Yancheng Biotechnology Co., Ltd. entered into a collaborative development project with Dr. He Zhonggui, a specially appointed prof
On November 2nd, 2023, Hengqin Yancheng Biotechnology Co., Ltd. was officially registered in the Hengqin Guangdong-Macao In-Depth Cooperation Zone, China. As a
On September 21, 2022, the 9th Innovation and Entrepreneurship Achievement Exchange, hosted by the All-China Federation of Returned Overseas Chinese, was held i
APAC Pharmaceutical (HK) Co., Ltd., integrated the operations of China Qianyue Company, founded in 2018, with business presence in Shenzhen, Taizhou, Suzhou, Na
